Clinical Trials


Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar

This study has been completed
Right to Care

Community Partners International
Myanmar Liver Foundation
Boston University
University of California, Los Angeles
Ministry of Health and Sports, Myanmar

Information provided by (Responsible Party)
Right to Care Identifier

First received: June 24, 2018
Last updated: July 26, 2019
Last Verified: June 2018
History of Changes


The project will evaluate cost and treatment outcomes of a simplified hepatitis C virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations including people who inject drugs (PWID) in Myanmar.

Condition Intervention
Hepatitis C
Hepatitis B
HIV Infections

Drug : sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar

Further study details as provided by Right to Care:

Primary Outcome Measures

  • Estimated cost of HCV screening per patient screened and per case identified and the cost per successfully treated patient for HCV mono-infected and co-infected participants [ Time Frame: Two years. This will be after data on Viral load response is complete. ]
    The average cost to the provider per patient achieving SVR12 will be estimated, as will the average cost per other outcomes achieved, such as per patient screened and per patient remaining in care by other specified endpoints, stratified by HIV status and by any other important patient or site characteristics that are identified as drivers of cost. The study will also estimate the average cost to "produce" a successful outcome (SVR12), which is the ratio of total costs for the intervention for the entire sample enrolled to the number of patients achieving the primary outcome. This latter estimate captures the costs incurred for patients who do not have successful outcomes and thus relates resource utilization to health outcomes.
  • Overall Sustained Viral load response (SVR12) across all groups of HCV genotype, fibrosis stage, HIV and HBV co-infection. [ Time Frame: 24 weeks ( 12 weeks post treatment) ]
    This will be the main treatment outcome of all patients initiated on treatment. Baseline viral load is done at entry with treatment initiated for those positive and eligible. Patients initiated on treatment will be assessed for viral load response at 24 weeks ( 12 weeks post treatment). This will also help in development of Care cascade for HCV testing, treatment and SVR12 in key populations co-infected with HIV/HCV, HIV/HCV/HBV, HBV/HCV and HCV mono-infected.
Secondary Outcome Measures:
  • HCV genotype and subtype [ Time Frame: At baseline ]
    HCV Genotype and subtypes will be determined at entry for all patients. Frequency of resistance associated substitutions (RAS) among participants registered for the project will also be determined.
  • Validity and reliability of Cepheid GeneXpert in monitoring SVR12 [ Time Frame: Testing done at baseline and 24 weeks ]
    150 patients will be evaluated for HCV viral load at entry and exit ( SVR12) comparing cepheid Gene Xpert and Roche real time PCR ( Standard method)
  • HIV Viral load among HCV/HIV co-infected patients [ Time Frame: HIV Viral load at 24 weeks ( 12 weeks post HCV treatment) ]
    HCV/HIV co-infected patients will either be on treatment at the time of HCV treatment initiation but those not on ART will be initiated and will assess rates of ART initiation and virologic suppression of HIV-infected persons within the simplified HCV testing and treatment model.

Biospecimen Retention: Samples Without DNA
Dry Blood spots ( DBS) will collected at baseline, 4, 8, 12 and 24 weeks for viral load and resistance testing will be determination where applicable

Enrollment: 803
Study Start Date: December 20, 2017
Study Completion Date: June 30, 2019
Primary Completion Date: March 30, 2019 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
HCV infected patients
All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
Drug: sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.

Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.

Detailed Description:

Affected populations will be screened for HCV and HIV and treated with direct a fixed-dose combination of sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin. Before and after completion of the treatment course viral load assessments will be undertaken using low-cost laboratory monitoring for comparison to standard HCV viral load measurement. Up to 800 patients enrolled on treatment will be followed up at 4, 8, 12 and 24 weeks when Sustained Viral Load ( SVL) will be determined. Safety monitoring will be undertaken at applicable visits for those on Ribavirin and all adverse events will be reported based on Good Clinical Practice. In addition to assessing to assessing cost outcomes, the project will assess HCV treatment efficacy in terms of sustained virologic response at 12 weeks after end of HCV treatment (defined as undetected HCV RNA or less than lower limit of detection), compare the cost of low cost HCV viral assay platforms to standard of care, assess rates of ART initiation and virologic suppression of HIV-infected persons within the simplified HCV testing and treatment model and impact of HIV co-infection in participants on the HCV treatment outcome of sustained virologic response (SVR12). The project will be conducted 3 treatment sites in Yangon, Mandalay, and Kachin state in Myanmar.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  
Sampling Method: Probability Sample  

Study Population

The target population are key population including Female Sex Workers, Men who have sex with men and People Who Use InjecaAll HCV-infected men and women aged 18 years or older. The study population eligible for HCV treatment will be HCV treatment naïve or experienced (pegylated interferon [PegIFN] and ribavirin [RBV] only), HCV-infected men and women aged 18 years or older with HCV genotype 1, 2, 3, 4, 5 or 6, with or without HIV-1 co-infection. Participants with compensated cirrhosis (Child-Pugh Class A) and hepatitis B infection will be eligible for HCV treatment. Patients with decompensated liver cirrhosis (Child-Pugh Class B or C) or prior treatment with HCV DAAs will not be eligible for treatment.


Inclusion Criteria:

    1. Ability and willingness of participant to provide informed consent.
    2. Men and women age 18 years.
    3. Active HCV infection as defined by detectable serum or plasma HCV RNA at any time prior to study entry. Documentation may be obtained from medical records if available. NOTE: If no medical records on HCV infection are available, active HCV infection must be confirmed by a detectable HCV RNA PCR prior to project entry.
    4. Allowed HCV treatment history:
        1. HCV treatment naïve defined as not having been previously treated for Hepatitis C infection with any medications approved for the treatment of HCV in any country.
        2. HCV treatment experienced with interferon with or without ribavirin only (no prior DAA treatment).
      1. Chronic Hepatitis B status must be documented by hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (HBcAb) testing. Participants with positive HBsAg must be already on an active HBV regimen at study entry.
      2. HIV-1 infection status must be documented as either absent or present, as defined below:
          1. Absence of HIV-1 infection, as documented by rapid HIV test or HIV-1 enzyme immunoassay (ELISA) test kit, within 60 days prior to entry.

        1. Presence of HIV-1 infection, documented by rapid HIV test or HIV-1 ELISA test kit at any time prior to entry.

      3. HIV-1 infection confirmed by medical documentation as participant is registered in care at AIDS Center and receiving or preparing to initiate ARV treatment.
    5. HIV co-infected participants taking ART or planning to initiate ART, should be:
        1. Tolerating ART for at least 2 weeks without signs of needing to modify or discontinue the ART regimen before initiating HCV treatment.

      1. The ART regimen must be a regimen that can be co-administered with SOF/VEL.
    6. Participants who are assigned to receive ribavirin as part of the treatment protocol must have hemoglobin ≥11.0 g/dL
    7. For females of reproductive potential who will receive ribavirin, a negative urine pregnancy test (urine -HCG with a sensitivity of <25 mIU/mL) within 48 hours prior to project entry (HCV treatment initiation) must be documented.
    8. Male and female participants who are able to impregnate or become pregnant (ie, of reproductive potential) and are participating in sexual activity that could lead to pregnancy must agree to practice contraception/birth control as indicated below or agree to not participate in a conception process while on treatment with ribavirin through at least 12 weeks post-treatment.
    9. Life expectancy >12 months, in the opinion of the site investigator

Exclusion Criteria:
    1. Child-Pugh Score corresponding to Class B or C (decompensated cirrhosis). This requires assessment for encephalopathy and ascites, as well as measurement of serum bilirubin, albumin, and international normalized ratio (prothrombin time).
    2. Breastfeeding or pregnancy if patient will be receiving ribavirin.
    3. Known allergy/sensitivity or any hypersensitivity to components of drug(s) or their formulation.
    4. Acute tuberculosis (TB) infection. They will be followed and offered enrolment when they complete TB treatment.
    5. Renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 or end-stage renal disease receiving dialysis as treatment with SOF/VEL is contraindicated (
    6. Unwilling to provide informed consent for participation in the project.
    7. Prior treatment with any HCV Direct Acting Agents (DAA).
    8. Unable or unwilling to adhere to the HCV treatment course and monitoring in the
    opinion of the investigator.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03579576


Kāchen, Kachin, Myanmar
Myanmar Liver Foundation Clinic
Mandalay, Myanmar
Myanmar Liver Foundation Charity Clinic
Yangon, Myanmar

Sponsors and Collaborators

Right to Care
Community Partners International
Myanmar Liver Foundation
Boston University
University of California, Los Angeles
Ministry of Health and Sports, Myanmar


Study Chair: Ian Sanne, MBBCH,FRCP Right to Care
Principal Investigator: Khin Pyone Khi, MBBS,FRCP,PhD Myanmar Liver Foundation
Study Director: Charles Chasela, PhD Right to Care
More Information

More Information

Responsible Party: Right to Care Identifier: NCT03579576   History of Changes  
Other Study ID Numbers: EQUIPHCV01-MY  
Study First Received: June 24, 2018  
Last Updated: July 26, 2019  

Studies a U.S. FDA-regulated Drug Product: No  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by Right to Care:


Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis B
Velpatasvir processed this data on June 02, 2020
This information is provided by